Key result
Review summarizes the latest evidence on diagnosing and treating arrhythmias in PAH and CTEPH.
Why the study?
Despite their impact on symptoms, morbidity, in-hospital mortality, and sudden death, comprehensive data on arrhythmia epidemiology, pathophysiology, and outcomes in PAH and CTEPH remain lacking.
This review synthesizes current evidence on the mechanisms, epidemiology, and clinical management of arrhythmias in patients with PAH and CTEPH.
Arrhythmias worsen morbidity and mortality in PAH/CTEPH; leaves open evidence-based management strategies.
Arrhythmias are increasingly recognized as severe complications of precapillary pulmonary hypertension, encompassing pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Despite their significant contribution to symptoms, morbidity, in-hospital mortality, and potentially sudden death in PAH/CTEPH, there remains a lack of comprehensive data on epidemiology, pathophysiology, and outcomes to inform the management of these patients. This review provides an overview of the latest evidence on this subject, spanning from the molecular mechanisms underlying arrhythmias in the hypertrophied or failing right heart to the clinical aspects of epidemiology, diagnosis, and treatment.
No takes yet. Share an insight, caveat, or question.
Abouzaid et al. (2024) conducted a review in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. This review summarizes the latest evidence on the epidemiology, pathophysiology, diagnosis, and treatment of arrhythmias in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: